Moolec Science (Moolec Science) Debt-to-EBITDA : -1.25 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Moolec Science Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Moolec Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.39 Mil. Moolec Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.95 Mil. Moolec Science's annualized EBITDA for the quarter that ended in Dec. 2023 was $-6.66 Mil. Moolec Science's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -1.25.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Moolec Science's Debt-to-EBITDA or its related term are showing as below:

MLEC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.27 Med: -0.05 Max: -0.05
Current: -1.27

During the past 3 years, the highest Debt-to-EBITDA Ratio of Moolec Science was -0.05. The lowest was -1.27. And the median was -0.05.

MLEC's Debt-to-EBITDA is ranked worse than
100% of 276 companies
in the Biotechnology industry
Industry Median: 1.37 vs MLEC: -1.27

Moolec Science Debt-to-EBITDA Historical Data

The historical data trend for Moolec Science's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moolec Science Debt-to-EBITDA Chart

Moolec Science Annual Data

Trend

Jun21

Jun22

Jun23

Debt-to-EBITDA

N/A

-0.05

Moolec Science Quarterly Data
	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial					-	-0.09	-0.23	-0.46	-1.25

Competitive Comparison of Moolec Science's Debt-to-EBITDA

For the Biotechnology subindustry, Moolec Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moolec Science's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Moolec Science's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Moolec Science's Debt-to-EBITDA falls into.

Moolec Science Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Moolec Science's Debt-to-EBITDA for the fiscal year that ended in Jun. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.546	+	0.099)	/	-51.741
	=	-0.05

Moolec Science's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(2.39	+	5.945)	/	-6.66
	=	-1.25

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Moolec Science (NAS:MLEC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Moolec Science Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Moolec Science's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Moolec Science (Moolec Science) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moolec Science SA (NAS:MLEC) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

17, Boulevard F.W. Raiffeisen, Luxembourg, LUX, L-2411

Website

https://www.moolecscience.com

Moolec Science SA is a science-based ingredient company focused on producing real animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. Its purpose is to upgrade the taste, nutrition, and affordability of alternative protein products while building a more sustainable and equitable food system.